Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DNA X, Inc.SONM · Entity 8261 | Chief Financial Officer | February 09, 2026 | February 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DNA X, Inc.
Report date February 09, 2026 · Filed February 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,719 |
Reported balance
After 2026-02-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-09 · Grant · Acquired 35,000 · Balance 36,719 F1: Represents the grant of restricted stock units that vest in equal monthly installments over a one-year period following the date of the grant, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F2: Consists of (i) 1,719 shares of common stock and (ii) 35,000 unvested restricted stock units. F3: The number of securities reported herein reflects the effects of a 1-for-18 reverse stock split effected by the Issuer on October 27, 2025, which was exempt from reporting pursuant to Rule 16a-9. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units that vest in equal monthly installments over a one-year period following the date of the grant, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.
F2: Consists of (i) 1,719 shares of common stock and (ii) 35,000 unvested restricted stock units.
F3: The number of securities reported herein reflects the effects of a 1-for-18 reverse stock split effected by the Issuer on October 27, 2025, which was exempt from reporting pursuant to Rule 16a-9.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 09, 2026 Filed Feb 11, 2026 01:55 UTC | DNA X, Inc. SONM · Entity 8261 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-006055 · ownership.xml · nonDerivative · entry 1 Crolius Clayton · CIK 0001937013 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,719 F1 · shares: Represents the grant of restricted stock units that vest in equal monthly installments over a one-year period following the date of the grant, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Consists of (i) 1,719 shares of common stock and (ii) 35,000 unvested restricted stock units. F3 · balance_after: The number of securities reported herein reflects the effects of a 1-for-18 reverse stock split effected by the Issuer on October 27, 2025, which was exempt from reporting pursuant to Rule 16a-9. Read SEC document |
| April 23, 2025 Filed Apr 25, 2025 12:35 UTC | DNA X, Inc. SONM · Entity 8261 | SaleCommon Stock | 11,634 | $1.45 | $16,869.30 |
DisclosureSEC source: 0001641172-25-006117 · ownership.xml · nonDerivative · entry 1 Crolius Clayton · CIK 0001937013 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,958 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales are mandated by the Issuer's election under its equity incentive plan to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.42 to $1.45, inclusive. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a securityholder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 06, 2025 Filed Feb 11, 2025 02:30 UTC | DNA X, Inc. SONM · Entity 8261 | GrantCommon Stock | 33,922 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-005765 · ownership.xml · nonDerivative · entry 1 Crolius Clayton · CIK 0001937013 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,592 F1 · shares: Represents the grant of restricted stock units that vest in two equal installments on the 90th and 180th day following the date of the grant, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Consists of (i) 8,670 shares of common stock and (ii) 33,922 unvested restricted stock units. F3 · balance_after: The number of securities reported herein reflects the effects of a 1-for-10 reverse stock split effected by the Issuer on July 17, 2024, which was exempt from reporting pursuant to Rule 16a-9. Read SEC document |
| April 08, 2024 Filed Apr 10, 2024 00:58 UTC | DNA X, Inc. SONM · Entity 8261 | GrantEmployee Stock Option (Right-to-Buy) · Derivative | 170,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001493152-24-014120 · ownership.xml · derivative · entry 1 Crolius Clayton · CIK 0001937013 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2034-04-08 F1 · derivative.exercise_date: The options will vest over the next three (3) years in equal yearly installments on each anniversary of the grant date. Read SEC document |
| November 24, 2023 Filed Nov 27, 2023 23:35 UTC | DNA X, Inc. SONM · Entity 8261 | GrantEmployee Stock Option (Right-to-Buy) · Derivative | 200,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001493152-23-042816 · ownership.xml · derivative · entry 1 Crolius Clayton · CIK 0001937013 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-11-24 F1 · derivative.exercise_date: The options vest in their entirety on the first anniversary of the grant date. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 00:45 UTC | DNA X, Inc. SONM · Entity 8261 | PurchaseCommon Stock | 86,700 | $0.68 | $59,216.10 |
DisclosureSEC source: 0001493152-23-032976 · ownership.xml · nonDerivative · entry 1 Crolius Clayton · CIK 0001937013 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,700 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.635 to $0.71, inclusive. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a securityholder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 23:00 UTC | DNA X, Inc. SONM · Entity 8261 | GrantEmployee Stock Option (Right-to-Buy) · Derivative | 100,000 | $0.00 Strike: $0.49 | $0.00 |
DisclosureSEC source: 0001493152-23-003189 · ownership.xml · derivative · entry 1 Crolius Clayton · CIK 0001937013 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-01-27 F1 · derivative.exercise_date: The options vest in their entirety on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.